Detalhe da pesquisa
1.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Lancet
; 386(9992): 444-51, 2015 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26037941